We are live on ! Find out more
RJFSA

Raymond James Financial Services Advisors Portfolio holdings

AUM $75.1B
1-Year Est. Return 31.89%
This Fund
S&P 500
This Quarter Est. Return
+5.67%
1 Year Est. Return
+31.89%
3 Year Est. Return
+38.17%
5 Year Est. Return
+106.56%
10 Year Est. Return
+236.84%
AUM
$16B
AUM Growth
+$364M
Cap. Flow
-$374M
Cap. Flow %
-2.34%
Top 10 Hldgs %
13.67%
Holding
2,790
New
234
Increased
1,278
Reduced
908
Closed
258

Sector Composition

Rank Sector Weight
1 Technology 8.43%
2 Financials 6.74%
3 Healthcare 6.54%
4 Consumer Staples 5.82%
5 Industrials 5.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NXEOW
2476
DELISTED
Nexeo Solutions, Inc. Warrant
NXEOW
$19K ﹤0.01%
30,000
WG
2477
DELISTED
Willbros Group
WG
$19K ﹤0.01%
13,194
CYTR
2478
DELISTED
CytRx Corp
CYTR
$19K ﹤0.01%
11,494
-2,948
-20% -$6.1K
AEMD icon
2479
Aethlon Medical
AEMD
$1.66M
0
OESX icon
2480
Orion Energy Systems
OESX
$80.6M
$18K ﹤0.01%
2,010
-20
-1% -$184
ATNM icon
2481
Actinium Pharmaceuticals
ATNM
$25M
$17K ﹤0.01%
840
+233
+38% +$4.69K
T icon
2482
CALL
AT&T
T
$163B
$17K ﹤0.01%
+20,787
New +$568K
FG.WS
2483
DELISTED
FGL Holdings Warrants exercisable for one Ordinary Share at a price of $11.50 per share
FG.WS
$17K ﹤0.01%
+11,000
New +$15.8K
EGLT
2484
DELISTED
Egalet Corporation
EGLT
$17K ﹤0.01%
16,884
-5,325
-24% -$5.73K
STI
2485
CALL
DELISTED
SunTrust Banks, Inc.
STI
$15K ﹤0.01%
+11,100
New +$678K
NVIV
2486
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$15K ﹤0.01%
1
COOP
2487
DELISTED
Mr. Cooper
COOP
$14K ﹤0.01%
1,384
-388
-22% -$3.73K
GILD icon
2488
CALL
Gilead Sciences
GILD
$165B
$14K ﹤0.01%
34,000
+10,100
+42% +$767K
HURA
2489
TuHURA Biosciences
HURA
$136M
$14K ﹤0.01%
1
PTN
2490
Palatin Technologies
PTN
$13.8M
$13K ﹤0.01%
12
NMTR
2491
DELISTED
9 Meters Biopharma
NMTR
$13K ﹤0.01%
109
CATX icon
2492
Perspective Therapeutics
CATX
$342M
$12K ﹤0.01%
3,000
MBII
2493
DELISTED
Marrone Bio Innovations, Inc.
MBII
$12K ﹤0.01%
11,061
-5,000
-31% -$5.11K
NNA
2494
DELISTED
Navios Maritime Acquisition Corporation
NNA
$12K ﹤0.01%
+694
New +$13.1K
PHIO icon
2495
Phio Pharmaceuticals
PHIO
$12.1M
0
NNVC icon
2496
NanoViricides
NNVC
$36.2M
$10K ﹤0.01%
556
VXRT
2497
DELISTED
Vaxart
VXRT
$9K ﹤0.01%
1,477
+182
+14% +$1.27K
CRIS icon
2498
Curis
CRIS
$7.83M
$8K ﹤0.01%
6
+1
+20% +$2.35K
PG icon
2499
CALL
Procter & Gamble
PG
$339B
$8K ﹤0.01%
13,500
EBAY icon
2500
CALL
eBay
EBAY
$49.8B
$7K ﹤0.01%
+12,500
New +$464K

Similar funds

Raymond James Financial Services Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Raymond James Financial Services Advisors held 2,790 positions worth $16B, up 2.3% from $15.6B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Raymond James Financial Services Advisors's Q4 2017 filing shows 234 new, 1,278 increased, 908 reduced and 258 closed positions. Its largest new stake was JPMorgan Diversified Return US Mid Cap Equity ETF: 221,656 shares worth $14.1M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $279M.

By sector, the portfolio is most concentrated in Technology at 8.4% of assets, up from 7.7% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James Financial Services Advisors's largest Q4 2017 buy was JPMorgan Diversified Return US Mid Cap Equity ETF: 221,656 shares worth $14.1M.
  • Raymond James Financial Services Advisors added most to Vanguard S&P 500 ETF in Q4 2017, an estimated $43.1M increase.
  • Raymond James Financial Services Advisors's biggest Q4 2017 reduction was PepsiCo, cutting an estimated $34.9M.
  • Raymond James Financial Services Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q4 2017, selling an estimated $279M.
  • Raymond James Financial Services Advisors's ten largest holdings make up 14% of its $16B portfolio in Q4 2017.
  • Raymond James Financial Services Advisors opened 234 new positions and closed 258 in Q4 2017.
  • Raymond James Financial Services Advisors's portfolio value rose 2.3% quarter-over-quarter to $16B.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.